Decoding the Science of Life
Nanobiotix has reported complete-cohort results from a Phase 1 study of radiotherapy-activated JNJ-1900, also called NBTXR3, in patients with inoperable,…
Ultragenyx has reported that its Phase 3 Aspire study of apazunersen, also called GTX-102, in Angelman syndrome did not meet…
FDA has approved Lisraya, or brepocitinib, tablets for adults with dermatomyositis, creating the first FDA-approved oral treatment option for this…
Not every important healthcare development arrives as a new drug approval or a dramatic clinical-data release. Sometimes the real bottleneck…
One of the most overlooked healthcare developments of the last forty-eight hours came not from a drug trial, a reimbursement…
The most interesting biotech development of the last forty-eight hours is not a dramatic efficacy surprise or another acquisition headline.…
The most interesting biotech development of the last forty-eight hours is not a new mechanism in early discovery or a…
In biotech, investors often overreact to early efficacy hints and underappreciate the strategy hiding underneath them. The more interesting July…
The global biotech ecosystem is currently living through a critical data paradox. Researchers have unprecedented access to high-resolution biological information…
Biotech policy has spent the last several years talking as if national competitiveness were mainly a question of patents, subsidies,…
Ozempic and Wegovy have become household names for weight loss, but a wave of new research reveals they are reshaping…
